You might benefit from reading the triangle report.
The $20k number you keep quoting is not for cardioprotection, it's for cardioprotection and anti cancer synergy. It is impossible to provide cardioprotection without also triggering anti-cancer targets. I don't know of a single informed investor that is here for cardioprotection on it's own, because a drug exists and it's not an exciting commercial opportunity. I am here for CPACS because it's never accomplished before in humans.
Bisantrene has achieved a response in 22 cancer types, leads all approved single agent drugs in R/R AML for CR rate, and has so far demonstrated universal cardioprotection. Publications on Losartan as a potential CPACS have been around since 2019, and it has been investigated in a fair few clinical trials dating back to 2013. The cardioprotection in humans is weak as there are multiple other drugs used off label to treat cardiotoxicity, and none of the trials completed to date that I have read suggest strong synergy.
Gee, must be a very active agent. Did I tell you Bisantrene leads all other approved drugs in AML through completely novel mechanisms?
Cardioprotection thread, page-708
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |